



Flexion Therapeutics, Inc.
 Investor Relations Department
 10 Mall Road
 Suite 301
 Burlington, MA 01803
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: FLXN	
Last Trade:	21.00
Trade Time:	9:48 AM ET Jun 28, 2017
Change:	0.17 ↑ (+0.816%)
Day Range	20.69 - 21.21
52-Week Range	14.50 - 29.41
Volume	23,296

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006), is an extended release intra-articular, analgesic candidate in late stage development for moderate to severe osteoarthritis pain.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 28, 2017*
[Flexion Therapeutics Announces Appointment of Mark Levine as General Counsel](#)
- Jun 23, 2017*
[Flexion Therapeutics Named One of Boston Business Journal's Best Places to Work](#)
- Jun 10, 2017*
[Flexion Therapeutics to Present Data on Zilretta™ \(FX006\) at the American Diabetes Association's 77th Scientific Sessions](#)
- May 22, 2017*
[Flexion to Present New Cost-Effectiveness Data on Zilretta™ \(FX006\) at the International Society for Pharmacoeconomics and Outcomes Research 22nd International Meeting](#)
- May 18, 2017*
[Flexion Therapeutics Announces Upcoming Data Presentation at the American Diabetes Association's 77th Scientific Sessions](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 10, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 5, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 3, 2016*
[Quarterly Report \(10-Q\)](#)